Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00068224 · ClinicalTrials.gov registry record
Clinical and Molecular Investigations Into Ciliopathies
A clinical trial, sponsored by National Human Genome Research Institute (NHGRI).
- Completed
- Registry status
- 374
- Enrollment target
NCT00068224: Completed study, sponsored by National Human Genome Research Institute (NHGRI).
NCT00068224 is a clinical trial that has completed, run by National Human Genome Research Institute (NHGRI). The registered enrollment target is 374 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00068224 has completed, sponsored by National Human Genome Research Institute (NHGRI).
- COMPLETED
- Registry status
- 374 participants
- Enrollment target
Study Summary
This study will evaluate patients ciliopathies. People with ciliopathies develop fibrocystic disease of the kidneys and liver, retinal degeneration, obesity, structural and functional defects of the central nervous system and the eyes, abnormal bone growth, abnormal sidedness of internal organs and polydactyly. The goal of the study is to better understand the medical complications of these disorders and identify characteristics that can help in the design of new treatments.
Primary Outcome
The general objective of this study is to assess the clinical characteristics of ciliopathies.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 374 participants |
| Start Date | 2003-03-16 |
| Est. Completion | 2021-02-18 |
What the finished NCT00068224 record still lists
NCT00068224 is an observational study that tracks outcomes without assigning an intervention. The registered 374 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00068224 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00068224 about?
NCT00068224 is a clinical study titled "Clinical and Molecular Investigations Into Ciliopathies". This study will evaluate patients ciliopathies. People with ciliopathies develop fibrocystic disease of the kidneys and liver, retinal degeneration, obesity, structural and functional defects of the central nervous system and the eyes, abnormal bone growth, abnormal sidedness of internal organs and ...
What is the current status of trial NCT00068224?
This trial is currently completed. The enrollment target is 374 participants. The study started on 2003-03-16. Estimated completion is 2021-02-18.
Who is sponsoring clinical trial NCT00068224?
This trial is sponsored by National Human Genome Research Institute (NHGRI), which has 185 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03686124 · 375 participants · Phase 1
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- NCT04059172 · 375 participants · Early Phase 1
Efficacy of Combined Ibuprofen and Acetaminophen Therapy Versus Ibuprofen Alone Versus Placebo Alone for Pain Management
- NCT04134923 · 375 participants
Imaging Biomarkers in Preclinical and Symptomatic AD
- NCT04569747 · 375 participants · Phase 2
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI